Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers
Cancer Control · 2024-01 · 31
DOI: 10.1177/10732748241305237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Control, online erschienen am 05.12.2024. Verfasst von Jianan Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Zhejiang Chinese Medical University, Hangzhou, P.R. China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Nomograms, Bile Duct Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Immune therapy, especially involving PD-1/PD-L1 inhibitors, has shown promise as a therapeutic option for cholangiocarcinoma. However, limited studies have evaluated survival outcomes in cholangiocarcinoma patients treated with immune therapy. This study aims to develop a predictive model to evaluate the survival benefits of immune therapy in patients with cholangiocarcinoma.
Methods
This retrospective analysis included 120 cholangiocarcinoma patients from Shulan (Hangzhou) Hospital. Univariate and multivariate Cox regression analyses were conducted to identify factors associated with survival following immune therapy. A predictive model was constructed and validated using calibration curves (CC), decision curve analysis (DCA), concordance index (C-index), and receiver operating characteristic (ROC) curves.
Results
Cox regression analysis identified several factors as potential predictors of survival post-immune therapy in cholangiocarcinoma: treatment cycle (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School, Zhejiang Chinese Medical University, Hangzhou, P.R. China.
- Department of Oncology, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, P.R. China.
ORCID-Profile: Jianan Jin
Zitieren
APA
Jin, J., Mou, H., Zhou, Y., & Zhang, S. (2024). Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers. Cancer Control, 31. https://doi.org/10.1177/10732748241305237
Vancouver
Jin J, Mou H, Zhou Y, Zhang S. Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers. Cancer Control. 2024;31. doi:10.1177/10732748241305237
BibTeX
@article{Jin2024,
author = {Jin, Jianan and Mou, Haibo and Zhou, Yibin and Zhang, Shiqi},
title = {Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers},
journal = {Cancer Control},
year = {2024},
volume = {31},
doi = {10.1177/10732748241305237}
}
EUVIMED